What question did this study set out to answer?

The research aims to validate plasma p-217tau as a reliable biomarker for neurological diseases like Alzheimer's disease.

March 12, 2026Open Access

View Full Paper

Clinical Validation of Plasma p‐217tau in Neurological Diseases

TKTakeshi Kawarabayashi TNTakumi NakamuraUniversity of Tsukuba RTRyoma TakahashiGunma University

Key Points

The research aims to validate plasma p-217tau as a reliable biomarker for neurological diseases like Alzheimer's disease.
Assessment of plasma p-217tau levels in patients with ALS and iNPH.
Comparison of biomarker levels with clinical symptoms of neurological diseases.
Analysis of association between p-217tau levels and specific neurological impairments.
Elevated plasma p-217tau levels were significantly associated with lower motor neuron injury in ALS.
Cognitive dysfunction in iNPH also correlated with increased plasma p-217tau levels.
Findings suggest that p-217tau could serve as a biomarker for distinguishing neurological conditions.

Abstract

ALS and iNPH are two major pitfalls for the clinical application of plasma p-217tau as a biomarker of AD. Lower motor neuron injury in ALS and cognitive dysfunction in iNPH were both found to be associated with elevated plasma p-217tau levels.

AI से पूछें

Bookmark

View Full Paper

Cite This Study

Kawarabayashi et al. (Mon,) studied this question.

synapsesocial.com/papers/69b2587296eeacc4fcec81b0 https://doi.org/https://doi.org/10.1002/acn3.70359

AI से पूछें

Bookmark

View Full Paper